Darizmetinib

DB21627InvestigationalSmall molecule

Darizmetinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Darizmetinib is a tyrosine kinase inhibitor. Darizmetinib has a monoisotopic molecular weight...

Mechanism: Pharmacologically active on Dual specificity mitogen-activated protein kinase kinase 4
Curator reviewed
Formula / weight: C₂₁H₁₇F₂N₅O₃S · 457.46 g/mol (avg)
Code names: HRX-0215 · LN-3348

Resolves to

Compound

UNIIQ2HX6A3UDWCAS2369583-33-3ChEMBLCHEMBL4795907ChEBI758449PubChem139369660

Structure

InChIKeyWBNMARNYIFMNEP-UHFFFAOYSA-NSMILESCCCS(=O)(=O)NC1=C(F)C=CC(C(=O)C2=NNC3=NC=C(C=C23)C2=CC=NC=C2)=C1F

Targets

P45985MAP2K4

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Darizmetinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account